ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Coronavirus

Japan takes different track than US on COVID-19 antibody treatments

Takeda alliance focuses on therapy derived from patients' blood

A researcher holds a test tube of antibodies: Regeneron and Eli Lilly are among the companies developing coronavirus treatments.   © Reuters

TOKYO -- With antibody treatments seen as the best weapon against COVID-19, Japan and the country's top drugmaker have turned to a type derived from the plasma of recovered patients, rather than the lab-made varieties used on U.S. President Donald Trump.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more